BioSpace News Archive

BrainStorm announced positive data from a Phase II safety and efficacy study of NurOwn in progressive MS on Thursday morning.

A large part of the funding will go to the research and development of CIN-107 as it has shown the potential to treat primary aldosteronism and treatment-resistant hypertension.

The drug is limited to patients who test at least 20% for a Ki-67 score on an FDA-approved test.

CRISPR Therapeutics provided updated data from its ongoing Phase I CARBON trial of CTX110, its allogeneic “off-the-shelf” CAR-T therapy for CD19+ B-cell cancers.

Genome-editing company Intellia Therapeutics and France-based SparingVision have partnered to develop new therapies for ocular diseases. The deal could be worth up to $600 million for Intellia.

Investors are dropping dollars into the life sciences industry like the trees are dropping their leaves. Here’s who’s raking in the cash this week.

It’s not the COVID-19 vaccine that will get you. The real cause for concern is the virus, and it lies in the fact that both male and female reproductive organs contain cell receptors the virus targets.

Bone Biologics Corp., a developer of orthobiologic products for spine fusion markets, announced the pricing of its underwritten public offering of 1,510,455 units of securities at an offering price of $5.25 per unit, for total gross proceeds of $7.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Varian, a Siemens Healthineers company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its Embozene ® microspheres for genicular artery embolization (GAE) for symptomatic knee osteoarthritis.

Generate Life Sciences today announced it is donating a Sepax 2 S-100 cell bioprocessing system manufactured by Cytiva to Rutgers Cancer Institute of New Jersey to support investigation of the potential efficacy of cord blood infusions in a variety of pediatric brain injuries.